Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 12/2014

01.12.2014 | Article

Rapid emergence of daptomycin resistance in clinical isolates of Corynebacterium striatum… a cautionary tale

verfasst von: E. McElvania TeKippe, B. S. Thomas, G. A. Ewald, S. J. Lawrence, C.-A. D. Burnham

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to investigate the observation of daptomycin resistance in Corynebacterium striatum, both in vivo and in vitro. We describe a case of C. striatum bacteremia in a patient with a left ventricular assist device (LVAD); the initial isolate recovered was daptomycin susceptible with a minimum inhibitory concentration (MIC) of 0.125 μg/ml. Two months later, and after daptomycin therapy, the individual became bacteremic with an isolate of C. striatum with a daptomycin MIC of >256 μg/ml. To study the prevalence of daptomycin resistance in C. striatum, clinical isolates of C. striatum were grown in broth culture containing daptomycin to investigate the emergence of resistance to this antimicrobial. Molecular typing was used to evaluate serial isolates from the index patient and the clinical isolates of C. striatum we assayed. In vitro analysis of isolates from the index patient and 7 of 11 additional C. striatum isolates exhibited the emergence of high-level daptomycin resistance, despite initially demonstrating low MICs to this antimicrobial agent. This phenotype was persistent even after serial subculture in the absence of daptomycin. Together, these data demonstrate that caution should be taken when using daptomycin to treat high-inoculum infections and/or infections of indwelling medical devices with C. striatum. To our knowledge, this is the first report characterizing the emergence of daptomycin resistance in C. striatum.
Literatur
4.
Zurück zum Zitat Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, Pigrau Serrallach C, Guerra Farfán E, Amat Mateu C, Flores Sanchez X (2012) Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 67(7):1749–1754. doi:10.1093/jac/dks119 CrossRefPubMed Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, Pigrau Serrallach C, Guerra Farfán E, Amat Mateu C, Flores Sanchez X (2012) Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 67(7):1749–1754. doi:10.​1093/​jac/​dks119 CrossRefPubMed
5.
Zurück zum Zitat Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, Agrusta F, Caprioli R, Albisinni R, Ragone E, Utili R (2012) High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54(3):347–354. doi:10.1093/cid/cir805 CrossRefPubMed Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, Agrusta F, Caprioli R, Albisinni R, Ragone E, Utili R (2012) High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54(3):347–354. doi:10.​1093/​cid/​cir805 CrossRefPubMed
6.
Zurück zum Zitat Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) (2014) University of Alabama at Birmingham. Accessed 3 Feb 2014 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) (2014) University of Alabama at Birmingham. Accessed 3 Feb 2014
8.
Zurück zum Zitat Funke G, von Graevenitz A, Clarridge JE 3rd, Bernard KA (1997) Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 10(1):125–159PubMedPubMedCentral Funke G, von Graevenitz A, Clarridge JE 3rd, Bernard KA (1997) Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 10(1):125–159PubMedPubMedCentral
9.
Zurück zum Zitat Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT (2003) In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47(6):1968–1971CrossRefPubMedPubMedCentral Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT (2003) In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47(6):1968–1971CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT (2003) In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47(1):337–341CrossRefPubMedPubMedCentral Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT (2003) In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47(1):337–341CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200(12):1916–1920. doi:10.1086/648473 CrossRefPubMedPubMedCentral Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200(12):1916–1920. doi:10.​1086/​648473 CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104(22):9451–9456. doi:10.1073/pnas.0609839104 CrossRefPubMedPubMedCentral Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104(22):9451–9456. doi:10.​1073/​pnas.​0609839104 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365(10):892–900. doi:10.1056/NEJMoa1011138 CrossRefPubMedPubMedCentral Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365(10):892–900. doi:10.​1056/​NEJMoa1011138 CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Munita JM, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Arias CA (2013) A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 57(6):2831–2833. doi:10.1128/AAC.00021-13 CrossRefPubMedPubMedCentral Munita JM, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Arias CA (2013) A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 57(6):2831–2833. doi:10.​1128/​AAC.​00021-13 CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA (2012) Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56(8):4354–4359. doi:10.1128/AAC.00509-12 CrossRefPubMedPubMedCentral Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA (2012) Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56(8):4354–4359. doi:10.​1128/​AAC.​00509-12 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S (2009) Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. J Clin Microbiol 47(7):2328–2331. doi:10.1128/JCM.00457-09 CrossRefPubMedPubMedCentral Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S (2009) Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. J Clin Microbiol 47(7):2328–2331. doi:10.​1128/​JCM.​00457-09 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Tran TT, Jaijakul S, Lewis CT, Diaz L, Panesso D, Kaplan HB, Murray BE, Wanger A, Arias CA (2012) Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother 56(6):3461–3464. doi:10.1128/AAC.00046-12 CrossRefPubMedPubMedCentral Tran TT, Jaijakul S, Lewis CT, Diaz L, Panesso D, Kaplan HB, Murray BE, Wanger A, Arias CA (2012) Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother 56(6):3461–3464. doi:10.​1128/​AAC.​00046-12 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat McElvania Tekippe E, Shuey S, Winkler DW, Butler MA, Burnham CA (2013) Optimizing identification of clinically relevant Gram-positive organisms by use of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system. J Clin Microbiol 51(5):1421–1427. doi:10.1128/JCM.02680-12 CrossRefPubMedPubMedCentral McElvania Tekippe E, Shuey S, Winkler DW, Butler MA, Burnham CA (2013) Optimizing identification of clinically relevant Gram-positive organisms by use of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system. J Clin Microbiol 51(5):1421–1427. doi:10.​1128/​JCM.​02680-12 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez M, Burnham CA (2013) Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 57(1):559–568. doi:10.1128/AAC.01633-12 CrossRefPubMedPubMedCentral Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez M, Burnham CA (2013) Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 57(1):559–568. doi:10.​1128/​AAC.​01633-12 CrossRefPubMedPubMedCentral
26.
27.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2013) Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI document M100-S23. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2013) Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI document M100-S23. CLSI, Wayne, PA
28.
Zurück zum Zitat Ghide S, Jiang Y, Hachem R, Chaftari AM, Raad I (2010) Catheter-related Corynebacterium bacteremia: should the catheter be removed and vancomycin administered? Eur J Clin Microbiol Infect Dis 29(2):153–156. doi:10.1007/s10096-009-0827-0 CrossRefPubMed Ghide S, Jiang Y, Hachem R, Chaftari AM, Raad I (2010) Catheter-related Corynebacterium bacteremia: should the catheter be removed and vancomycin administered? Eur J Clin Microbiol Infect Dis 29(2):153–156. doi:10.​1007/​s10096-009-0827-0 CrossRefPubMed
30.
Zurück zum Zitat Fernández Guerrero ML, Robles I, Nogales Mdel C, Nuevo D (2013) Corynebacterium striatum: an emerging nosocomial drug-resistant endocardial pathogen. J Heart Valve Dis 22(3):428–430PubMed Fernández Guerrero ML, Robles I, Nogales Mdel C, Nuevo D (2013) Corynebacterium striatum: an emerging nosocomial drug-resistant endocardial pathogen. J Heart Valve Dis 22(3):428–430PubMed
32.
33.
Zurück zum Zitat van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis 30(5):603–610. doi:10.1007/s10096-010-1128-3 CrossRefPubMed van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis 30(5):603–610. doi:10.​1007/​s10096-010-1128-3 CrossRefPubMed
Metadaten
Titel
Rapid emergence of daptomycin resistance in clinical isolates of Corynebacterium striatum… a cautionary tale
verfasst von
E. McElvania TeKippe
B. S. Thomas
G. A. Ewald
S. J. Lawrence
C.-A. D. Burnham
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2014
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2188-6

Weitere Artikel der Ausgabe 12/2014

European Journal of Clinical Microbiology & Infectious Diseases 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.